During the past decade, national biosafety systems have gained importance as mechanisms for ensuring the safe use of biotechnology products without imposing unacceptable risk to human health or the environment, or unintended constraints to technology transfer. This Country Report presents an analysis of the present status of the biosafety system in Egypt and its impact on the commercialization of genetically modified organisms (GMOs). The specific objectives of the report are:1. to assess the efficacy of biosafety policies and procedures associated with the introduction of biotechnology products in Egypt;2. to develop recommendations for enhancing the operation of Egypt's biosafety system and minimizing potential constraints to technology transfer;3. to identify areas where ISNAR and other international providers can provide furtherassistance.The report includes a description of the organization and operation of Egypt's biosafety system, and discusses the larger context for GMO commercialization. Recommendations emerging from this study include (1) specific suggestions for revising Egypt's biosafety guidelines, (2) ideas for improving the functioning of national and institutional biosafety committees, (3) recommendations for strengthening biosafety review and decision making, and (4) developing means of actively disseminating information to the wider biotechnology community and the public.Findings and recommendations in the report may serve as the basis for discussions to strengthen and adapt the biosafety system to the changing context for biotechnology products in Egypt.